Hims Roller Coaster Continues with Surprise Losses, Soft Sales and Lower Guidance

Hims stock plunged early Tuesday after the telehealth giant missed Wall Street’s third-quarter sales forecast, reported surprise losses and lowered the midpoint of its outlook for 2026. The news follows a deal with Eli Lilly (LLY) that will allow Hims & Hers Health (HIMS) to sell the company’s weight-loss drugs, Zepbound and Foundayo. Although its stock is limited…